Shares of Myovant Sciences Ltd.
gained 7% in premarket trading on Tuesday after the drugmaker said a late-stage clinical trial for its experimental endometriosis drug hit its primary and secondary endpoints. The relugolix combination therapy helped reduce pain among the studied segment of patients with endometriosis. "Women need and deserve treatment options beyond surgery, and these data indicate relugolix combination therapy has the potential to substantially reduce pain while improving function and activities of daily living and decreasing the proportion of women on opioids," Dr. Eric Brown, an obstetrician-gynecologist and an investigator for the study, said in a news release. The company's stock is up 12.8% year-to-date, while the S&P 500
is down 3.5%.